Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyruan Plus is a pharmaceutical drug containing high molecular weight sodium hyaluronate, primarily indicated for the treatment of osteoarthritis, particularly in the knee and shoulder joints. It functions as a viscoelastic supplement, aiming to restore the lubricating and shock-absorbing properties of synovial fluid within the affected joints. This action helps to reduce friction, alleviate pain and inflammation, and improve overall joint mobility. Additionally, it has been noted for use as a surgical aid in various ophthalmic procedures, including cataract extraction, intraocular implantation, corneal transplant, glaucoma filtration, and retinal attachment surgery. The drug is administered via intra-articular injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hyruan Plus.